BioSpace News Archive

Feb. 19, 2020 11:00 UTC HUNTINGTON BEACH, Calif.--( BUSINESS WIRE )-- Cicero Diagnostics Inc., a women’s healthcare diagnostic company, is pleased to announce the awarding of a $1 million Phase II SBIR Fast Track grant from the National Institutes of Health (NIH). The grant, titled “SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity” follows completion of Phase I, successfully demonstrating concordance of the protein markers BCL6 and SIRT1 to endometr

IRVING, Texas , Feb. 19, 2020 /PRNewswire/ -- Caris Life Sciences ® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Brian Brille , Vice Chairman of the Company, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 , at 9:30 a.m. Eastern time . The confe

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment in the two highest dose groups of its Phase 1/2 clinical trial evaluating the safety and efficacy of sub-retinal injection of AGTC-501 for the treatment of X-linked retinit

SAN CARLOS, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2019 financial results on Tuesday, February 25, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST. To participate in the conference call, please dial 1-844-646-4465 (domes

BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call:

OLDWICK, N.J. , Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9 th Annual SVB Leerink Global Healthcare Conference on Wednes

NEWARK, Calif. , Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York . Presentation details: Event: SVB Leerink 9th Annual Global Healthcare Confere

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will provide a corporate overview at the Cowen & Co. 40 th Annual Healthcare Conference, and the 32 nd Annual ROTH Conference. Cowen & Co. 40 th Annual Healthcare Conference Date:

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the 9 th Annual SVB Leerink Global Healthcare Conference. The fireside chat will take place on Wednesda

DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Tuesday, February 25 at 8:30 a.m. ET to discuss the Company’s fourth quarter and full-year 2019 financial results and corp